Invivyd, Inc. (IVVD) NASDAQ
1.60
+0.01(+0.63%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.60
+0.01(+0.63%)
Currency In USD
| Previous Close | 1.59 |
| Open | 1.6 |
| Day High | 1.64 |
| Day Low | 1.57 |
| 52-Week High | 3.07 |
| 52-Week Low | 0.48 |
| Volume | 1.24M |
| Average Volume | 3M |
| Market Cap | 212.37M |
| PE | -5.33 |
| EPS | -0.3 |
| Moving Average 50 Days | 1.59 |
| Moving Average 200 Days | 1.61 |
| Change | 0.01 |
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
GlobeNewswire Inc.
Mar 05, 2026 12:01 PM GMT
Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women’s Hospital, Dr. Mina strengthens Invivyd’s medical leadershi
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
GlobeNewswire Inc.
Mar 02, 2026 9:10 PM GMT
NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday,
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Mar 02, 2026 9:01 PM GMT
NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on March 1, 2026, Invivyd granted four newly hired non-executive employees options to purchase an aggregate of 192,000 shares of its common stock